[Ip-health] FW: New study on 2 Hepatitis C medicines' impact on health spending

BAGOZZI, Daniela bagozzid at who.int
Thu Jun 2 02:04:34 PDT 2016

Hi all,
Sorry for this second posting but it was brought to my attention that the below implies Sue Hill was the principal author of this paper when in fact it was Swathi Iyengar.  Sue Hill initiated the process and is of course a co-author.  So for the sake of accuracy and for Swathi, please see this as an amendment to my earlier posting.
From: BAGOZZI, Daniela
Sent: 01 June 2016 09:57
To: Ip-health at lists.keionline.org
Subject: New study on 2 Hepatitis C medicines' impact on health spending

New study published yesterday in PLOS Medicine, by Suzanne Hill (WHO) et al, shows that the prices of sofosbuvir and ledipasvir/sofosbuvir vary greatly between countries worldwide, raising serious concerns about the viability of reducing the global hepatitis C burden.  For example, after adjusting for average 2015 exchange rates and purchasing power, the study reveals that the cost of treating the entire hepatitis C infected population in each of the 30 countries examined would range from 10.5% of total pharmaceutical expenditure in the Netherlands to 190.5% in Poland.

See study here: http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002032<redir.aspx?REF=VZsAnD-ldnhEM86bA8iCQ9CGaMXjIqZhPJYwQ9F7hjxe7rmLxIrTCAFodHRwOi8vam91cm5hbHMucGxvcy5vcmcvcGxvc21lZGljaW5lL2FydGljbGU_aWQ9MTAuMTM3MS9qb3VybmFsLnBtZWQuMTAwMjAzMg..>

More information about the Ip-health mailing list